Biotech · Private company
Hanmi Pharmaceutical Company Limited
Track this companyFree. Adds Hanmi Pharmaceutical Company Limited to your Dealase workspace and tells you when its record changes.
Clinical trials228 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- efpeglenatide (SAR439977)Phase 3 · Type 2 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- HM15136Phase 2 · Congenital HyperinsulinismClinicalTrials.gov · fetched Nov 12, 2026
- HM15211Phase 2 · NASH - Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- HM15275Phase 2 · Type 2 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- HM15275Phase 2 · ObeseClinicalTrials.gov · fetched Nov 12, 2026
- HM15912 ActivePhase 2 · Short Bowel SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- HM61713Phase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- BH3120Phase 1 · Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- HM12460APhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- HM12460APhase 1 · Type 2 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- HM15136Phase 1 · Obese With ComorbiditiesClinicalTrials.gov · fetched Nov 12, 2026
- HM15211Phase 1 · NAFLDClinicalTrials.gov · fetched Nov 12, 2026
- HM15275Phase 1 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- HM15912Phase 1 · Renal ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- HM16390Phase 1 · Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- HM17321Phase 1 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumabPhase 1 · Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials22
- Study to Evaluate HM15275 in Subjects With Type 2 Diabetes MellitusPHASE2 · RECRUITING · started May 18, 2026ClinicalTrials.gov NCT07527650 · fetched Nov 12, 2026
- Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes MellitusPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 2, 2025ClinicalTrials.gov NCT07205900 · fetched Nov 12, 2026
- A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese ParticipantsPHASE1 · RECRUITING · started Nov 6, 2025ClinicalTrials.gov NCT07219589 · fetched Nov 12, 2026
- A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry DiseasePHASE1_PHASE2 · RECRUITING · started May 14, 2025ClinicalTrials.gov NCT06858397 · fetched Nov 12, 2026
- Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid TumorsPHASE1 · RECRUITING · started Dec 11, 2024ClinicalTrials.gov NCT06724016 · fetched Nov 12, 2026
- A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.PHASE1 · COMPLETED · started May 28, 2024ClinicalTrials.gov NCT06481098 · fetched Nov 12, 2026
- Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid TumorsPHASE1 · RECRUITING · started Dec 28, 2023ClinicalTrials.gov NCT06234397 · fetched Nov 12, 2026
- Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney FunctionPHASE1 · COMPLETED · started Dec 2, 2022ClinicalTrials.gov NCT05711381 · fetched Nov 12, 2026
- HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)PHASE2 · ACTIVE_NOT_RECRUITING · started May 5, 2022ClinicalTrials.gov NCT04732416 · fetched Nov 12, 2026
- Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF SubjectsPHASE2 · RECRUITING · started Mar 3, 2022ClinicalTrials.gov NCT04775706 · fetched Nov 12, 2026
- Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)PHASE2 · COMPLETED · started Jul 31, 2020ClinicalTrials.gov NCT04505436 · fetched Nov 12, 2026
- Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With ComorbiditiesPHASE1 · COMPLETED · started Aug 30, 2019ClinicalTrials.gov NCT04167553 · fetched Nov 12, 2026
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With SulfonylureaPHASE3 · TERMINATED · started Aug 1, 2019ClinicalTrials.gov NCT03770728 · fetched Nov 12, 2026
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)PHASE3 · TERMINATED · started Nov 9, 2018ClinicalTrials.gov NCT03713684 · fetched Nov 12, 2026
- A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLDPHASE1 · COMPLETED · started Nov 1, 2018ClinicalTrials.gov NCT03744182 · fetched Nov 12, 2026
- Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminPHASE3 · TERMINATED · started Sep 26, 2018ClinicalTrials.gov NCT03684642 · fetched Nov 12, 2026
- Effect of Efpeglenatide on Cardiovascular OutcomesPHASE3 · TERMINATED · started Apr 27, 2018ClinicalTrials.gov NCT03496298 · fetched Nov 12, 2026
- A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)PHASE1 · COMPLETED · started Apr 4, 2018ClinicalTrials.gov NCT03374241 · fetched Nov 12, 2026
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and ExercisePHASE3 · COMPLETED · started Dec 5, 2017ClinicalTrials.gov NCT03353350 · fetched Nov 12, 2026
- Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes MellitusPHASE1 · TERMINATED · started Oct 25, 2017ClinicalTrials.gov NCT03332836 · fetched Nov 12, 2026
- Molar Potency Study of HM12460A in Healthy SubjectsPHASE1 · COMPLETED · started Oct 24, 2017ClinicalTrials.gov NCT03330314 · fetched Nov 12, 2026
- Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the LungPHASE2 · TERMINATED · started Aug 31, 2015ClinicalTrials.gov NCT02485652 · fetched Nov 12, 2026